Stocks In News (AEGR, LLY, KO, TSLA, THLD)

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)surged up 6.07% to $18.51.According to report fromReuters, U.S. drug reviewers were positive on Aegerion Pharmaceuticals's experimental drug for lipid disorder and said it showed a greater reduction in bad cholesterol as compared with statins. The FDA said an approval of the drug would require a risk evaluation and mitigation strategy to ensure that the benefits of lomitapide outweigh the risk of serious liver injury.

Eli Lilly & Co (NYSE:LLY) went up 0.61% to $52.85.Eli Lilly & Co was upgraded from market perform rating to outperform rating in a research report. Recently, r the company said that trials on a drug for treating stomach cancer had met the goals of improved patient survival and progression-free survival in a late-stage study that compared it to a dummy treatment.

The company said in a statement that the most common side effects for the medicine, ramucirumab, were high blood pressure, diarrhoea and headache.

The drug was tested in patients with gastric cancer that had spread to other parts of the body.

The Coca-Cola Company(NYSE:KO) soared 0.18% to $38.20 on a traded volume of 189k shares.Coca-Cola Hellenic Bottling SA intends to move its main stock listing from Athens to London as Greece’s largest company by market value flees the epicenter of Europe’s debt crisis.Coca-Cola Hellenic Bottling SA isthe world’s second-largest Coca-Cola bottler.The move will make it eligible for inclusion in the benchmark FTSE 100 Index.

Tesla Motors Inc(NASDAQ:TSLA) went up 0.37% to $27.43. The Company has received a $10 million grant from California to buy assembly equipment and add 500 workers to build a rechargeable sport-utility vehicle in the state.

Threshold Pharmaceuticals Inc (NASDAQ:THLD) surged up 9.33% to $5.74 on a traded volume of 54k shares.The U.S. Food and Drug Administration reached agreement with a Threshold partner covering a special protocol assessment for a Phase 3 trial of TH-302. This will allow the Companies to push forward the study of the pancreatic cancer drug.TH-302 is a potential treatment of metastatic or locally advanced unresectable pancreatic cancer

You have read this article AEGR / KO / LLY / THLD / TSLA with the title AEGR. You can bookmark this page URL http://calliecountrychatter.blogspot.com/2012/10/stocks-in-news-aegr-lly-ko-tsla-thld.html. Thanks!

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) Stocks Rise On High Cholesterol Drug Report

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) has risen after a US regulatory staff mentioned about a plan to tackle the risks of a company’s drug.

Aegerion has gained 9.40% to $17.46 in Monday’s session. This was after the declaration of the staff report from Food and Drug Administration. An advisory panel is supposed to meet on 17^th October on the medicine lomitapide. It is the lead product candidate of Aegerion based in Massachusetts. FDA is supposed to make a final decision on this by the end of December.

The pill is supposed to be taken everyday and it aims at treating a hereditary condition known as familial hypercholesterolemia about abnormalities in liver cells responsible for clearing LDL (low density lipoprotein) particles from blood. The ailment can result in heart attack or death at a early age, as per the National Institutes of Health. The consultative panel will consider a similar drug from Isis Pharmaceuticals and Sanofi on 18^th October.

The risk plan would support suitable use of lomitapide, allowing it to be permitted for use in the projected patient population with life threatening illness and limited therapeutic choices.

The FDA may need risk evaluation and mitigation strategies that go beyond drug labeling to make sure the benefits of a medication compensate the risks.

An analyst at Think Equity Partners in San Francisco said in a telephone interview that it does not believe that larger studies will be required given the REMs. The FDA has recommended the REMs agenda to better evaluate the drug safety.

Out of 19 patients in a clinical test, 17% has experienced the presence of an amplified enzyme in their blood that shows signs of liver damage. The FDA suggests Aegerion’ risk management plan include educating prescribers about liver risks and the need for checking patients with blood tests. 

You have read this article Aegerion Pharmaceuticals / AEGR / Inc. (NASDAQ:AEGR) / NASDAQ:AEGR with the title AEGR. You can bookmark this page URL http://calliecountrychatter.blogspot.com/2012/10/aegerion-pharmaceuticals-inc-nasdaqaegr.html. Thanks!